| Bioactivity | PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment[1]. |
| Target | PAD4 |
| Name | PAD4-IN-3 |
| CAS | 2642327-44-2 |
| Formula | C21H26BClN4O4 |
| Molar Mass | 444.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jia Y et al. Chitosan nanomedicine containing RGD peptide and PAD4 inhibitor based on phenyl boronate coupling inhibition of primary tumor growth and lung metastasis. Biomed Pharmacother. 2023 Dec;168:115826. |
PAD4-IN-3
CAS: 2642327-44-2 F: C21H26BClN4O4 W: 444.72
PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linke
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.